CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
HealthDay on MSN12h
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionThe U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Interesting Engineering on MSN3h
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback